MARKET NEWS

AVEO Oncology Announces Ficlatuzumab Granted Fast Track Designation by US FDA for the Treatment of Relapsed or Recurrent Head & Neck Squamous Cell Carcinoma
Carrick Therapeutics Debuts Data for First-In-Class Oral CDK7 Inhibitor Samuraciclib
Cue Biopharma Granted US Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101
Veru Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men With Metastatic Castration-Resistant Prostate Cancer
ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19
Micropore Technologies Announced as a Winner in Heathrow Airport’s Global Britain Business Champion Competition

  FEATURED EDITORIAL

 

  COMPANY PROFILE

Emergent CDMO is dedicated to helping pharma and biotech innovators bring lifesaving therapies to patients from around the world. Our nine development and manufacturing sites in North America and Europe can support early to late stage production of biotherapeutics and vaccines. Whether you’re looking for initial process development support, small volumes of material for clinical trials, or large-scale production for a global commercial therapy, our experienced CDMO team is ready to serve as your trusted guide from molecule to market. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Credence MedSystems Secures .9 Million Financing to Enable Scaling of Innovative Drug Delivery & Connected Health Systems

Credence MedSystems Secures $39.9 Million Financing to Enable Scaling of Innovative Drug Delivery & Connected Health Systems

Credence MedSystems, Inc. recently announced it has closed a funding round with gross proceeds of $39.9 million. Sources of funding include strategic investments from Novartis Pharma AG,….

Novartis Announces Collaboration on HARMONIA, a Phase 3, Head-to-Head Trial Evaluating Kisqali Versus Ibrance in Patients With HR+/HER2- Advanced Breast Cancer

Novartis Announces Collaboration on HARMONIA, a Phase 3, Head-to-Head Trial Evaluating Kisqali Versus Ibrance in Patients With HR+/HER2- Advanced Breast Cancer

Novartis recently announced a collaboration with SOLTI Innovative Cancer Research (SOLTI) on HARMONIA, an international, randomized, Phase 3, multicenter, open-label study of….

Clarus Therapeutics & McGill University Announce Exclusive Worldwide Licensing Agreement to Develop & Commercialize Technology to Treat Rare Conditions Associated With Coenzyme-Q10 (Ubiquinone) Deficiencies

Clarus Therapeutics & McGill University Announce Exclusive Worldwide Licensing Agreement to Develop & Commercialize Technology to Treat Rare Conditions Associated With Coenzyme-Q10 (Ubiquinone) Deficiencies

Clarus Therapeutics Holdings, Inc. and McGill University recently announced a licensing agreement whereby Clarus will develop and commercialize McGill’s proprietary technology designed to treat….

FDA Approves Samsung Bioepis & Biogen’s BYOOVIZ (SB11), LUCENTIS Biosimilar (ranibizumab-nuna)

FDA Approves Samsung Bioepis & Biogen’s BYOOVIZ (SB11), LUCENTIS Biosimilar (ranibizumab-nuna)

Samsung Bioepis Co., Ltd. and Biogen Inc. recently announced the US FDA has approved BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTIS (ranibizumab) for the treatment of neovascular….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

October 6 – API Synthesis
October 13 – Bioavailability